Start main content

Business/ Service/ Function

Business/ Service/ Function

Technology Transfer Office:  Our Service Arm

The Technology Transfer Office (TTO) was established in 2006 to manage the University’s invention disclosures and intellectual property assets. It also promotes and facilitates the transfer of innovations and research discoveries made at HKU so as to benefit both the University community and the general public.

The TTO provides services and support to all University academic staff on matters relating to technology transfer, intellectual property protection, research-related collaborative or service contracts, applied research, and industrial and business relationships. When a project reaches the point where it is ready for a contract, it is passed to Versitech for contract negotiations and closure.

  • Facilitate intellectual property protection and commercialisation of technologies developed at HKU by
    • Evaluating applications to patent inventions, and the commercial viability of inventions
    • Overseeing patent and trademark undertakings
    • Drafting, scrutinizing and advising on research-related agreements
  • Develop links between the University and parties in technology commercialisation
  • Organize  educational events to foster an innovative and entrepreneurial culture at HKU


Versitech Limited: Our Business Arm

Versitech Limited ("港大科橋有限公司") is the commercial arm of HKU. It was established in 1994 as a wholly-owned subsidiary of the University and is incorporated as a non-profit company with prominent business people on its Board of Management. Versitech negotiates, executes and manages commercial business contracts and agreements on behalf of the University.

  • Undertake the commercialisation of HKU innovations and technologies through licensing, the creation of start-ups or collaboration.
  • Engage in contract research and consulting in conjunction with HKU researchers. This work is aimed at serving business and community needs.

Board of Management


Mr. Jason CHIU


Jason Chiu is the founder and CEO of Cherrypicks, a leader in mobile innovation, specializing in making cities smarter and growing the eLearning community. Jason is an industry icon in Hong Kong well known for his successful entrepreneurial experience in mobile innovation. With disruptive Online-to-Offline (O2O) solutions as well as patent-pending products and technology inventions, Cherrypicks has represented Hong Kong and China in many world stages and won over 100 local and international awards. The early entrepreneurial journey of the company was also featured as a Harvard Business School case study (#N9-807-106).


Cherrypicks' solution business and Cherrypicks alpha, another startup spun off with the company’s product business, were strategically merged with NetDragon (HKSE:777) in 2014 and 2016 respectively. Apart from leading both entities, Jason is also a mentor and angel investor for a number of startups, incubators and co-working spaces to give back to startups in Hong Kong and Silicon Valley.

Jason is the Honorary President of Group 30 “Creative Industries” and Chairman of the Hong Kong Startup Council under Federation of Hong Kong Industries. He is the Director of the Hong Kong Crowdfunding Professional Association, the Advisor of Crowdfund Capital Advisors, the Vice Chairman of Innovation and Technology Fund – General Support Programme Vetting Committee of Innovation and Technology Commission, a Council member of the Hong Kong Trade Development Council and the University of Hong Kong, a Board member of the Junior Achievement Hong Kong, as well as a Committee member of the HKTDC Belt and Road & Greater Bay Area Committee.


Professor Richard Y C WONG

Provost and Deputy Vice-Chancellor

Professor Y.C. Richard Wong, SBS, JP, is Chair of Economics and Philip Wong Kennedy Wong Professor in Political Economy. He joined the University of Hong Kong in 1992, served as Director of the School of Business from 1997 to 2001, founding Dean of the Faculty of Business and Economics from 2001 to 2004, and Provost and Deputy Vice-Chancellor during 2004-2010; he is appointed interim Provost and Deputy Vice-Chancellor from April 2019.

Professor Wong was educated at the University of Chicago. He taught at the Chinese University of Hong Kong from 1976 to 1992. His main research interest is in economic policy analysis and regional economic development. He is principal investigator of the University Grants Committee's Area of Excellence award for research in economic policy and business strategy.

He had served on numerous professional and public bodies and was awarded the Silver Bauhinia Star in 1999 for his contributions in education, housing, industry and technology development and was appointed a Justice of the Peace in 2000 by the Government of the Hong Kong Special Administrative Region.


Professor Alfonso H W NGAN

Acting Vice-President and Pro-Vice-Chancellor (Research)

Professor Alfonso H.W. Ngan is currently Kingboard Professor in Materials Engineering, and Chair Professor of Materials Science and Engineering. He obtained his BSc(Eng) degree from the University of Hong Kong in 1989 as the Williamson Prizeman (top Engineering graduate), and PhD from the University of Birmingham in the U.K. in 1992 with the Thomas Turner Prize (best thesis award). After a year of postdoctoral training at Oxford University supported by the Croucher Foundation, he joined HKU in 1993, and was promoted through the ranks to Chair Professorship in 2011. Prior to his current appointment as Acting Vice-President (Research), he served as Head of Department of Mechanical Engineering from 2017-19, and Associate Dean of Engineering from 2014-17.

Professor Ngan is a leading researcher in the microstructural basis of properties of engineering materials, in particular, crystalline defects and their modeling, and nanomechanics including applications to biological systems, as well as in novel actuating materials. His research-related honours include the prestigious Rosenhain Medal from the Institute of Materials, Minerals and Mining (IMMM), U.K., in 2007 – he is the first non-British national to have received this award since its establishment in 1951. He was also awarded a higher doctorate (DSc) from the University of Birmingham in 2008, the Croucher Senior Research Fellowship in 2009, and in 2014 he was elected to the Hong Kong Academy of Engineering Sciences (HKAES). He is frequently invited to international conferences, and has organized a number of key conferences, including Dislocations 2008 and Gordon Research Conference on Nanomechanical Interfaces in 2013, both held in Hong Kong, and was a Meeting Chair in the Materials Research Society 2017 Spring Meeting held in the USA. He is currently an Associate Editor of the International Journal of Plasticity. He is an elected Fellow of the IMMM and the Hong Kong Institution of Engineers (HKIE). He serves on the Executive Committee of the HKAES and the Accreditation Board of HKIE, and has played advisory roles in a number of government committees and Mainland institutions.

Dr. Yiwu He, PhD, MBA

Senior Advisor to the President/Chief Innovation Officer 

Dr. Yiwu He currently serves as the Senior Advisor to the President and Chief Innovation Officer of The University of Hong Kong. Prior to this appointment, Dr. He served many senior executive roles including the deputy director and senior program officer at the Bill & Melinda Gates Foundation, Senior Vice President and Global R&D Head at BGI, Global Head of Human Biomarker Centers at GlaxoSmithKline, the board director of P4 Medicine Institute, USA, as well as the chair professor at The University of Science and Technology of China. 

During his tenure at the Gates Foundation, Dr. Yiwu He was responsible for multiple global health programs including diagnostics, drug, and vaccine development. He managed the foundation's investments in the areas including HIV, TB, Pneumonia, Enteric Diarrhea, Polio and other infectious diseases. In addition, he established and managed multiple R&D programs in China under the directions of Bill Gates. He led multiple global initiatives involving countries from Africa, Southeast Asia, Europe and North America. He established significant networks globally for multilateral life science researches. His efforts in China helped the advancements of R&D of its biotech industry and particularly led to the large-scale vaccine productions with modern international standards that assured China's first and second vaccines pre-qualified by the World Health Organization. 

Before joining the Gates Foundation, Dr. He was with GlaxoSmithKline for 10 years serving in various roles, most recently as the Global Head and Senior Director of Human Biomarker Centers. He led and oversaw efforts of a global organization to discover and apply human biomarkers in understanding diseases, drug efficacies, and reactions to support clinical studies conducted by GSK. He led or was also involved in multiple drug development programs at GSK including Tykerb, Cervarix, Avandia, and Lamivudine. 

During his postdoc research at Harvard Medical School, he was involved in the development of the Angiogenesis theory against cancers. 

Mr. Hailson YU

Deputy Managing Director

Mr. Yu started his career as an assistant engineer at Ampex Ferrotec Limited, Hong Kong, in 1979. In 1982, he was promoted to equipment maintenance and calibration laboratory manager. Later, he was in charge of the computer engineering group and systems engineering group, responsible for the product development programs and the setting up of the CAD center.

In 1987, Mr. Yu joined China International Trust and Investment Corporation Hong Kong (Holdings) Limited (CITIC) as the General Manager - Engineering / Research & Development. He was seconded to a joint venture company (a computer manufacturing company) as the Deputy Managing Director and he successfully turned around its business. Next he oversaw the CITIC USA Venture Capital Fund, and he successfully listed two of the start-up companies in NASDAQ and sold four other companies for a profit.

His last appointment with CITIC was as Consultant of the Oil and Gas Development and of the LPG Tank Terminal Port investment projects, in which he played a significant role in project feasibility study and economic analysis, contract negotiation, and the setting up of the corresponding project companies. He joined Versitech Limited as the Deputy Managing Director in February 1998.

Mr. Yu has a Bachelor of Science and a Master of Science in Electrical Engineering, a Master of Arts in Arbitration and Dispute Resolution, a Post-graduate Certificate in Hong Kong Law and in Chinese Medicine, and a Postgraduate Diploma in Investment Management.

Mr. Yu is a Chartered Engineer. He is also a Fellow of the Institution of Electrical Engineers (IEE), the Hong Kong Institution of Engineers (HKIE), the Chartered Institute of Arbitrators (CIArb), and the Hong Kong Institute of Arbitrators (HKIArb).

Professor Victor O K LI

Professor Li was born in Hong Kong in 1954. He received his Bachelor of Science, Master of Science, Electrical Engineer, and Doctor of Science degrees in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology, Cambridge, Massachusetts, in 1977, 1979, 1980, and 1981, respectively.

He joined the University of Southern California (USC), Los Angeles, California, USA, in February 1981, and became Professor of Electrical Engineering and Director of the USC Communication Sciences Institute. Since September 1997, he has been with the University of Hong Kong (HKU), where he is Chair Professor of Information Engineering at the Department of Electrical and Electronic Engineering. He is also a director of Sunevision Holdings Ltd., iSSL Holdings Ltd., mCommerce Online Ltd., and IAR Ltd., and he serves on the advisory board of various technology companies. Professor Li was the Managing Director of Versitech Ltd from September 1997 to June 2004. His research interest is in information technologies, including high-speed communication networks, wireless networks, and distributed multimedia systems. Professor Li chairs various committees, workshops, and international conferences. He has given distinguished lectures and keynote addresses, and has consulted at various organizations around the world. He also serves on government panels, giving advice on the development of information technology and on technology transfer.

Professor Li has received numerous awards, including the PRC Ministry of Education Changjiang Chair Professorship at Tsinghua University, the UK Royal Academy of Engineering Senior Visiting Fellowship in Communications, the Outstanding Researcher Award of HKU, the Outstanding Research Student Supervisor Award of HKU, the Croucher Foundation Senior Research Fellowship, and the Bronze Bauhinia Star, Government of HKSAR, China.  He is a Fellow of the Hong Kong Academy of Engineering Sciences, the IEEE, the HKIE and the IAE.

Ms. Sara LO

Sara is the Director of Finance of the University of Hong Kong.  She is a qualified accountant and has extensive experience in University finance for about 20 years overseeing annual budgets over HK$5 billion and investment portfolio of about HK$12 billion.  She started her career in one of the big four audit firms for several years before joining the University.

Sara obtained her first degree in Social Sciences from HKU, and also completed an EMBA program offered by the University of Hong Kong Business School jointly with Columbia Business School and London Business School.  She is a Fellow of the Hong Kong Institute of Certified Public Accountants and of the Chartered Association of Certified Accountants.


Mr. K O Chia is Director of Grace Financial Ltd., a Hong Kong multi-family office where he focuses on direct investments and private equity investment program. He brings 30-plus years of diverse experience as U.S.-Asia venture capitalist, entrepreneurial journey with a successful telecom start-up and extensive corporate operational management with Hewlett-Packard/Agilent and Apple across Asia, Europe and U.S. 

He also serves as President of Hong Kong Venture Capital & Private Equity Association (HKVCA); Advisory Member on the School of Continuing Studies at Chinese University of Hong Kong; and Board of Versitech, University of Hong Kong technology transfer company. Previously he had served as Chairman of Advisory Committee, College of International Education at Hong Kong Baptist University; Board member of Cyberport Management, a HK government’s technology hub; and Committee Member of HKSAR government’s Community Investment & Inclusion Fund (CIIF) to seed social capital projects for community revival.

His current passion is in impact investments where he attempts to bring together venture capital investment discipline with an entrepreneurial approach to projects for double bottom line and community sustainability to alleviate systemic poverty.

He holds an MBA from Strathclyde Business School, Scotland; post graduate Diploma in Management Studies from Edinburgh Napier University, Scotland and BEng (Hons) Electronics Engineering from Sheffield University, England. He is also a Fellow of the Hong Kong Institute of Directors; a GlobalScot; Independent Director of family philanthropy, Seeds Foundation Ltd.; and Trustee on the Edinburgh Napier University Hong Kong Scholarship Trust.

Dr. Frank C W WAN

After having finished his primary and secondary schools, Dr. Wan left his birthplace, Hong Kong, to pursue his undergraduate studies at the University of Waterloo in Canada. He then received intensive training in cancer research on National Cancer Institute of Canada Research Studentships at the Ontario Cancer Institute under the supervision of Professor Tak Mak of the Faculty of Medicine of the University of Toronto.

He later changed his career to law. He completed his LL.B degree from the University of London, his PCLL at the University of Hong Kong with two distinctions and received Doctor of Juridical Science degree from the City University of Hong Kong.

With his background in biomedical sciences, he has, under the advice of Professor Tak Mak and his group, involved and worked with investors in Hong Kong and overseas to invest in biotech companies in USA and Canada since early 90's. He is a frequent speaker and commentator on issues relating to Biotechnology industry. He has served as an assessor of Small Entrepreneur Research Assistance Programme of Hong Kong Government since January 2004 and served on advisory panel of Life Science and Biotechnology of CityU's Applied Research Grant scheme. He has served as honorary legal advisor to a number of medical associations and was a former chairman of the Hong Kong Biotechnology Association Ltd.

Mr. Philip Y H FAN

Philip Yan Hok Fan was born and raised in Hong Kong. He graduated from La Salle Secondary School before going to college in the United States. He studied at Stanford University and obtained a B.S. degree in Industrial Engineering and a M.S. degree in Operation Research. Subsequently, he was awarded a fellowship by M.I.T. and graduated from its Sloan School of Management with a Master degree in Management.

In 1976, he went to Nigeria, a West African country in the midst of an oil boom he was appointed General Manager of a steel mill company established by a consortium of Hong Kong industrialists. In a few years, he became Managing Director of a steel rolling mill which he co-founded with partners. He operated that business successfully for some time before returning to Hong Kong at the end of the Nigerian oil boom in 1983.

In 1984, he joined the Material Science Products Division of Pfizer Inc. as Area Manager. He was in charge of sales and marketing of its products in the P.R.C., Taiwan and Malaysia. Later, he became consultant to Pfizer Inc's Minerals Division; he was able to play a significant role in obtaining approvals for the establishment of a minerals joint venture in China.

In 1990, he took his family to Canada. After living in Vancouver for three years, he returned to Hong Kong to join CITIC Hong Kong(Holdings) Ltd. In October 1993. He was named to the Board of CITIC Pacific Ltd. As of January 1, 1994. As an Executive Director of CITIC Pacific Ltd, he was appointed Chairman of the Board to three of its industrial joint ventures in China and Director to a number of other P.R.C. joint ventures covering businesses like power generation, telecommunication, underwater road tunnel and property development.

The most significant achievement while working at Citic Pacific was the establishment of Jiangyin Xingcheng Special Steel Works which has become a global leading manufacturer of specialty steel.

By the end of 1997, he joined China Everbright International Ltd. as Executive Director and General Manager. At the time the Company was a struggling conglomerate listed on the Hong Kong Stock Exchange. It was later successfully restructured with a focus on environmental infrastrure development. Since 2003, the China Everbright International Group has evolved into three listed companies. It has become the leader of the Chinese Waste-to-Energy industry and holds leadership positions in waste water treatment, biomass energy and hardzardous waste treatment in China.

In 2000, he retired from active management of China Everbright International but remained on its board as Non-Exeutive Director. He has been appointed to a number of boards of listed companies as Independent Non-Executive Director. Some of these listed companies are Hysan Development (HKSE:014), First Pacific (HKSE: 142), China Aircraft Leasing (HKSE:1848), and Goodman Group (GMG.AX). He had also served for four years on the Asia Advisory Committee of AustralianSuper, the largest Australian industrial pension fund.

Professor H L Henry CHAN

Dr Henry Chan is a specialist in dermatology. He is also currently the Honorary Clinical Professor of the Division of Dermatology, Department of Medicine, the University of Hong Kong and Honorary Consultant Dermatologist of Queen Mary Hospital, Hong Kong. He is Council and Court member of the University of Hong Kong, Board of Director of Versitech Limited, the University of Hong Kong, Member of Hospital Governing Committee of MacLehose Medical Rehabilitation Centre, Hospital Authority and Member of Board of Governors, Centennial College. He is a Steward of The Hong Kong Jockey Club.


Dr Chan obtained his Medical degree (MBBS) from The London Hospital Medical College, University of London, Master (M Sc Clinical dermatology) and his first Doctorate degree (MD), from King’s College, University of London. He then did his second Doctorate degree (PhD) from Li Ka Shing Faculty of Medicine, University of Hong Kong, part of his PhD was done at the Wellman Center for Photomedicine, Massachusetts General Hospital (MGH), a teaching affiliate of Harvard Medical School, Boston, USA. As a result, he has been a visiting faculty (research staff) at the Wellman Center, MGH since 2007 and was Visiting Associate Professor at Harvard Medical School from 2008 until 2010. Dr Chan’s work has led him to successfully obtained six patent families (five in Boston and one in Hong Kong).  In 2011, he and 3 other colleagues (Dr Rox Anderson, Dr Dieter Manstein and Dr Irina Erenburg) at MGH, Harvard Medical School set up an incubator company known as Blossom Innovations and sub-licensed these technologies back from MGH for further development. Subsequently, these technologies have been transferred to R2 Dermatology in California and AVAVA LLC in Boston.  He is a member of the Board of Director of Blossom Innovations, AVAVA and S3 Inject.


Dr Chan headed the academic division of both the University of Hong Kong (Associate Professor 2000 – 2004) and The Chinese University of Hong Kong (Associate Professor 1998 – 2000). He was the President of the Hong Kong College of Dermatologists (2009 – 2013) and the Honorary Secretary of the Asian Dermatological Association (1999 – 2011). He was also the Chairman of the Hong Kong Society of Dermatology and Venereology (2003 – 2005 & 2007 – 2009). Dr Chan has published or accepted to be published over 350 articles including 1 book, 37 book chapters and 146 peer reviewed international indexed publications (mean impact factor 3.23, total citation 3,625 and H Index: 38 (researcher ID number: L-2267-2013)). He is the Associate Editor of Lasers in Surgery and Medicine and serves on the editorial board of other international journals including the Dermatologic Surgery, Lasers in Medical Science, Journal of Cosmetic and Laser Therapy and Archives of Dermatological Research.


Dr Chan is currently the President-Elect of the American Society for Laser Medicine & Surgery (ASLMS, found in 1980, is the world largest Professional organization dedicated to promoting research, education and clinical care in the field of medical laser and energy-based applications) and will be the first non-American President in 2021. Dr Chan was the Conference Program Co-Chair for 2019 ASLMS annual conference in Denver. Dr Chan became one of the few non-American to be elected as a member of the ASLMS Board of Directors (2012-2015) and re-elected again in 2018 (2018-2021).  In 2010, Dr Chan became the first only non-American to be awarded the Ellet H Drake Memorial Award by ASLMS for his contribution to laser surgery. He was also the recipient of the ASLMS Presidential Citation in 2002, 2016 and 2018, ASLMS Best Session Award Clinical Applications – Cutaneous in 2018 and ASLMS Program Chair Recognition in 2019.


Dr Chan received the Presidential Award presented by the American Society for Dermatologic Surgery (ASDS) in 2014. In 2020, Dr Chan was awarded by The Sturge-Weber Foundation as one of the honorees.  In March 2016, Dr Chan was voted and elected by the membership of the American Dermatological Association as an International Honorary Member.  He was also an elected board member of Dermatologic Aesthetic Surgery International League (DASIL) (2011-2014) and an Honorary President of its annual congress in 2017. His other professional associations include Fellowships of the following institutions: the Royal College of Physicians of London, the Royal College of Physicians of Edinburgh, the Royal College of Physicians and Surgeons of Glasgow, Hong Kong College of Physicians and Hong Kong Academy of Medicine (Medicine).

Mr. Peter K S YAN

Mr Peter Yan is the Chief Executive Officer of the Hong Kong Cyberport Management Company Limited. As the CEO of Cyberport, Mr Yan leads the digital technology flagship to focus on fostering industry development, enterprise transformation and talent cultivation to realise Cyberport’s vision to create new impetus for Hong Kong’s new economy through digital technology.

Mr Yan has 34 years of experience in the information technology industry and is a fellow of the Hong Kong Computer Society. Prior to joining Cyberport, Mr Yan was the Executive Director and Chief Executive Officer of SUNeVision Holdings Limited; and had held various senior management positions in large consulting and information technology services companies including Accenture, Tradelink Electronic Commerce Limited, and Computer and Technologies Holdings Limited. Mr Yan has been active in public services especially in the areas of talent development and digital technology industry development, serving as advisors to the Chinese University of Hong Kong, City University of Hong Kong and University of Hong Kong, as well as the Board of Cyberport from 2011 to 2017.

Mr Yan holds a Bachelor’s degree in Business Administration from The Chinese University of Hong Kong, and received Executive Education from the Harvard Business School.

Ms. Anna X SUN

Ms. Anna Sun is the Executive Director of Nan Fung Life Sciences and the Director of Nan Fung Group CEO Office.  Ms. Sun had set up two VC funds under Nan Fung Sciences and in charge of the funds’ operation.    As a member of Nan Fung Life Sciences Investment Committee, she participates in investment decision making involving assets across various development stages.  She also facilitates the Nan Fung Group CEO’s Office in planning, driving and marketing new initiatives by conducting researches and providing business, operational and organizational analysis on initiatives driven by the Group CEO’s Office to facilitate top management’s decision marking.
Before joining Nan Fung, Ms. Sun was the Vice President of Rates Structuring Asia, Barclays Capital Asia Limited.  She was responsible for building structured solution business in Non Japan Asia and in charge of counterparty risk structuring in NJA (Public Side).
Ms. Sun received a Bachelor degree in Finance and minor in English in 2006 and a Master in Finance in 2008 from Tsinghua University.

Dr. Joseph W O TAM

Dr. Joseph Wing-On Tam is the Founder and Chairman of the Board of the Pangenia Group. Prior to retiring from HKU, Dr. Tam was a Visiting Professor of UCSF, Baylor Medical College, 湖南湘雅, 重庆医科大学 etc. He was one of the Founders and Presidents of the Hong Kong Biochemistry Association and member of international professional societies.
Dr. Tam has started working in rDNA research field in Hong Kong since the late 1970s, cloned the very first human Thalassemia DNA phage library in NIH, and identified few mutations in Chinese patients in 1980s.  In promoting DNA research in the region, he organized a rDNA training course with the support of UNESCO; brought in the pioneers to train young scientists in Hong Kong and Asia-Pacific Region in 1983. During his tenure at HKU, he travelled extensively in helping scientists to launch DNA research activities, especially in 2nd-ranked Universities; accepted and referred young scientists for overseas trainings to establish research activities and exchanges. The Fudan-HKU Sister University linkage and the Molecular Institute of Molecular Biology were byproducts of such activities. 

In Hong Kong Biotechnology industry, Dr. Tam is the original inventor and uses his US patented “flow-through hybridization technology” as platform for low density DNA array product for SNP mutation detection as well as pathogens identification. This platform is now used by other international companies such as Pamgene and Master Diagnostics. He formed the first university-industry joint venture using such platform and later successfully established companies such as Hybribio. DiagCor Bioscience Incorporation Limited, the important foundation of the Pangenia Group was founded in 2006 in Hong Kong. The Group has become the most comprehensive Molecular Diagnostic Laboratory in Hong Kong, and at the same time a place to cultivate local biotechnology talents. Dr. Tam is now concentrating to help some of the startups to help creating the ecosystem for Biotechnology in Hong Kong.

Dr. Edward C C TSE

Dr. Edward Tse is founder and CEO of Gao Feng Advisory Company, and a founding Governor of Hong Kong Institution for International Finance. One of the pioneers in China’s management consulting industry, he built and ran the Greater China operations of two leading international management consulting firms for a period of 20 years. He has consulted to hundreds of companies, investors, start-ups, and public-sector organizations (both headquartered in and outside of China) on all critical aspects of business in China and China for the world. He also consulted to the Chinese government on strategies, state-owned enterprise reform and Chinese companies going overseas, as well as to the World Bank and the Asian Development Bank. He is the author of several hundred articles and four books including both award-winning The China Strategy (2010) and China’s Disruptors (2015) (Chinese version «创业家精神»).


Last Updated: Jan 11, 2021

Contact Us / For Industry



Get the latest technology and news from us

Fields marked with asterisk (*) are required

If you do not wish to receive emails from us in the future, you can send an unsubscribe request to us by email to